Combination therapy in chronic active Epstein-Barr virus infection with multiple organs involvement：a case report and literature review

doi:10.12114/j.issn.1007-9572.2020.00.143

Abstract

Abstract: Chronic active Epstein-Barr virus infection（CAEBV） is an insidious disease with clinical manifestations and severity varying according to the site of involvement.Therefore，clinical management may be challenging.Currently，there is no universally acknowledged effective therapy for this disease.We reported a Chinese boy with CAEBV infection with intestinal，vascular，and neurological involvement using a treatment protocol including thalidomide and propranolol，ganciclovir and glucocorticoid.After treatment，the patient demonstrated a marked improvement in clinical symptoms，and was successfully cured.Literature review was also carried out.The report，together with the review may improve clinicians' understanding of CAEBV.Our treatment protocol shows promise as a safe and effective therapeutic approach for the disease.

Key words: Herpesvirus 4, human；Child；Thalidomide；Propranolol；Enteritis；Encephalitis

摘要： 慢性活动性EB病毒感染（CAEBV）的临床表现多样化，发病隐匿，因累及部位不同，导致其临床表现及病情严重程度不一样，临床的诊断及治疗具有一定的挑战性。对于该病目前无公认有效的治疗方法。本文报道了1例使用沙利度胺和普纳洛尔等联合治疗成功治愈的CAEBV合并肠炎、血管病变及脑炎病例，并进行了文献复习，以提高临床医师对CAEBV的认识。本例患儿予沙利度胺、普萘洛尔、更昔洛韦、糖皮质激素等治疗后临床症状消失，治疗方法安全有效，为CAEBV的治疗提供了新思路。

关键词: 疱疹病毒4型, 人；儿童；沙利度胺；普萘洛尔；肠炎；脑炎

XU Lingling,LIN Hongrong,BA Hongjun, et al. Combination therapy in chronic active Epstein-Barr virus infection with multiple organs involvement：a case report and literature review[J]. Chinese General Practice, 2020, 23(24): 3099-3103. DOI: 10.12114/j.issn.1007-9572.2020.00.143.
徐玲玲,林宏容,巴宏军等. 联合用药治疗慢性活动性EB病毒感染并多器官受累一例报道并文献复习[J]. 中国全科医学, 2020, 23(24): 3099-3103. DOI: 10.12114/j.issn.1007-9572.2020.00.143.

References

［1］OHSHIMA K，KIMURA H，YOSHINO T，et al．Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder （LPD） in children and young adults：overlap with chronic active EBV infection and infantile fulminant EBV T-LPD［J］．Pathol Int，2008，58（4）：209-217．DOI：10.1111/j.1440-1827.2008.02213.x.
［2］XIAO H J，LI J，SONG H M，et al．Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders manifested as gastrointestinal perforations and skin lesions：a case report［J］．Medicine （Baltimore），2016，95（5）：e2676．DOI：10.1097/MD.0000000000002676.
［3］ABDUL-GHAFAR J，KIM J W，PARK K H，et al．Fulminant Epstein-Barr virus-associated T-cell lymphoproliferative disorder in an immunocompetent middle-aged man presenting with chronic diarrhea and gastrointestinal bleeding［J］．J Korean Med Sci，2011，26（8）：1103-1107．DOI：10.3346/jkms.2011.26.8.1103.
［4］COHEN J I，KIMURA H，NAKAMURA S，et al．Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts：a status report and summary of an international meeting，8-9 September 2008［J］．Ann Oncol，2009，20（9）：1472-1482．DOI：10.1093/annonc/mdp064.
［5］COHEN J I，JAFFE E S，DALE J K，et al．Characterization and treatment of chronic active Epstein-Barr virus disease：a 28-year experience in the United States［J］．Blood，2011，117（22）：5835-5849．DOI：10.1182/blood-2010-11-316745.
［6］WASHIO K，OKA T，ABDALKADER L，et al．Gene expression analysis of hypersensitivity to mosquito bite，chronic active EBV infection and NK/T-lymphoma/leukemia［J］．Leuk Lymphoma，2017，58（11）：2683-2694．DOI：10.1080/10428194.2017.1304762.
［7］KIMURA H，COHEN J I.Chronic active Epstein-Barr virus disease［J］．Front Immunol，2017，8：1867．DOI：10.3389/fimmu.2017.01867.
［8］XING Y W，YANG J W，LIAN G H，et al．Chronic active Epstein-Barr virus infection associated with hemophagocytic syndrome and extra-nodal natural killer/T-cell lymphoma in an 18-year-old girl：a case report［J］．Medicine （Baltimore），2017，96（19）：e6845．DOI：10.1097/MD.0000000000006845.
［9］YAMASHITA H，SHIMIZU A，TSUCHIYA H，et al．Chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis exacerbation in a patient with systemic lupus erythematosus［J］．Lupus，2014，23（8）：833-836．DOI：10.1177/0961203314527367.
［10］ROLINSKI J，GRYWALSKA E，PYZIK A，et al．Interferon alpha as antiviral therapy in chronic active Epstein-Barr virus disease with interstitial pneumonia - case report［J］．BMC Infect Dis，2018，18（1）：190．DOI：10.1186/s12879-018-3097-6.
［11］NISHIMURA S，EHARA S，HANATANI A，et al．Chronic active Epstein-Barr virus infection complicated with multiple artery aneurysms［J］．Eur Heart J Cardiovasc Imaging，2014，15（11）：1255．DOI：10.1093/ehjci/jeu119.
［12］KOBAYASHI Z，TSUCHIYA K，TAKAHASHI M，et al．An autopsy case of chronic active Epstein-Barr virus infection （CAEBV）：distribution of central nervous system （CNS） lesions［J］．J Neurol Sci，2008，275（1/2）：170-177．DOI：10.1016/j.jns.2008.07.035.
［13］SONKE G S，LUDWIG I，VAN OOSTEN H，et al．Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients［J］．Clin Infect Dis，2008，47（1）：105-108．DOI：10.1086/588790.
［14］WANG Y X，LI Y J，MENG X W，et al．Epstein-Barr virus-associated T-cell lymphoproliferative disorder presenting as chronic diarrhea and intestinal bleeding：a case report［J］．Front Immunol，2018，9：2583．DOI：10.3389/fimmu.2018.02583.
［15］KOYAMA M，TAKESHITA Y，SAKATA A，et al．Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease［J］．Int J Hematol，2005，82（5）：437-440．DOI：10.1532/IJH97.05083.
［16］KIMURA H，MORISHIMA T，KANEGANE H，et al．Prognostic factors for chronic active Epstein-Barr virus infection［J］．J Infect Dis，2003，187（4）：527-533．DOI：10.1086/367988.
［17］ISHIHARA S，OKADA S，WAKIGUCHI H，et al．Chronic active Epstein-Barr virus infection in children in Japan［J］．Acta Paediatr，1995，84（11）：1271-1275．DOI：10.1111/j.1651-2227.1995.tb13547.x.
［18］ARAI A，NOGAMI A，IMADOME K，et al．Sequential monitoring of serum IL-6，TNF-α，and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy［J］．Int J Hematol，2012，96（5）：669-673．DOI：10.1007/s12185-012-1170-2.
［19］ARAI A，IMADOME K I，WATANABE Y，et al．Clinical features of adult-onset chronic active Epstein-Barr virus infection：a retrospective analysis［J］．Int J Hematol，2011，93（5）：602-609．DOI：10.1007/s12185-011-0831-x.
［20］SAWADA A，INOUE M，KAWA K.How we treat chronic active Epstein-Barr virus infection［J］．Int J Hematol，2017，105（4）：406-418．DOI：10.1007/s12185-017-2192-6.
［21］MATSUI S，TAKEDA Y，ISSHIKI Y，et al．Chronic active Epstein-Barr virus infection with marked pericardial effusion successfully treated with allogeneic peripheral blood stem cell transplantation［J］．Rinsho Ketsueki，2016，57（5）：624-629．DOI：10.11406/rinketsu.57.624.
［22］OKAMURA T，HATSUKAWA Y，ARAI H，et al．Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation［J］．Lancet，2000，356（9225）：223-224．DOI：10.1016/S0140-6736（00）02488-0.
［23］OKANO M，KAWA K，KIMURA H，et al．Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection［J］．Am J Hematol，2005，80（1）：64-69．DOI：10.1002/ajh.20398.
［24］MASHIMA K，YANO S，YOKOYAMA H，et al．Epstein-Barr virus-associated lymphoproliferative disorder with encephalitis following anti-thymocyte globulin for aplastic Anemia resolved with rituximab therapy：a case report and literature review［J］．Intern Med，2017，56（6）：701-706．DOI：10.2169/internalmedicine.56.7722.
［25］NODA Y，OHTSUKA Y，YASUI N，et al．A case of age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder which presented with encephalitis-like images［J］．Clin Neurol，2011，51（3）：207-210．DOI：10.5692/clinicalneurol.51.207.
［26］RAMAN L，NELSON M.Cerebral vasculitis and encephalitis due to Epstein-Barr virus in a patient with newly diagnosed HIV infection［J］．J Clin Virol，2014，59（4）：264-267．DOI：10.1016/j.jcv.2014.01.018.
［27］HAGEN R，GHAREEB E，JALALI O，et al．Infantile hemangiomas：what have we learned from propranolol?［J］．Curr Opin Pediatr，2018，30（4）：499-504．DOI：10.1097/MOP.0000000000000650.
［28］ROTTER A，DE OLIVEIRA Z N P.Infantile hemangioma：pathogenesis and mechanisms of action of propranolol［J］．J Ger Soc Dermatol：JDDG，2017，15（12）：1185-1190．DOI：10.1111/ddg.13365.
［29］JI Y，CHEN S，XU C，et al．The use of propranolol in the treatment of infantile haemangiomas：an update on potential mechanisms of action［J］．Br J Dermatol，2015，172（1）：24-32．DOI：10.1111/bjd.13388.
［30］D'AMATO R J，LOUGHNAN M S，FLYNN E，et al．Thalidomide is an inhibitor of angiogenesis［J］．Proc Natl Acad Sci USA，1994，91（9）：4082-4085．DOI：10.1073/pnas.91.9.4082.
［31］WEBER D，RANKIN K，GAVINO M，et al．Thalidomide alone or with dexamethasone for previously untreated multiple myeloma［J］．J Clin Oncol，2003，21（1）：16-19．DOI：10.1200/JCO.2003.03.139.